MIRM
Income statement / Annual
Last year (2025), Mirum Pharmaceuticals Inc's total revenue was $521.31 M,
an increase of 54.74% from the previous year.
In 2025, Mirum Pharmaceuticals Inc's net income was -$23.36 M.
See Mirum Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$521.31 M |
$336.89 M |
$186.37 M |
$77.06 M |
$19.14 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$100.58 M
|
$81.64 M
|
$47.04 M
|
$12.37 M
|
$1.90 M
|
$623.00 K
|
$324.00 K
|
$0.00
|
| Gross Profit |
$420.73 M
|
$255.25 M
|
$139.34 M
|
$64.69 M
|
$17.24 M
|
-$623.00 K
|
-$324.00 K
|
$0.00
|
| Gross Profit Ratio |
0.81
|
0.76
|
0.75
|
0.84
|
0.9
|
0
|
0
|
0
|
| Research and Development Expenses |
$186.18 M
|
$140.63 M
|
$102.61 M
|
$106.84 M
|
$131.43 M
|
$81.61 M
|
$42.99 M
|
$2.33 M
|
| General & Administrative Expenses |
$0.00
|
$190.72 M
|
$139.58 M
|
$0.00
|
$50.02 M
|
$22.69 M
|
$11.75 M
|
$877.50 K
|
| Selling & Marketing Expenses |
$0.00
|
$11.50 M
|
$6.30 M
|
$0.00
|
$9.20 M
|
$0.00
|
$0.00
|
-$292.50 K
|
| Selling, General & Administrative Expenses |
$257.03 M
|
$202.22 M
|
$145.88 M
|
$89.07 M
|
$59.22 M
|
$22.69 M
|
$11.75 M
|
$585.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$623.00 K
|
-$21.00 K
|
$0.00
|
| Operating Expenses |
$443.21 M
|
$342.85 M
|
$248.49 M
|
$195.91 M
|
$190.65 M
|
$103.67 M
|
$54.74 M
|
$2.92 M
|
| Cost And Expenses |
$543.45 M
|
$424.49 M
|
$295.53 M
|
$208.28 M
|
$192.55 M
|
$104.30 M
|
$54.74 M
|
$2.92 M
|
| Interest Income |
$12.73 M
|
$13.79 M
|
$13.74 M
|
$3.86 M
|
$366.00 K
|
$1.56 M
|
$2.23 M
|
$87.00 K
|
| Interest Expense |
$14.39 M
|
$14.31 M
|
$15.11 M
|
$15.98 M
|
$17.59 M
|
$335.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$24.24 M
|
$23.63 M
|
$10.83 M
|
$3.24 M
|
$975.00 K
|
$623.00 K
|
$324.00 K
|
$4.37 M
|
| EBITDA |
$17.21 M |
-$48.97 M |
-$136.49 M |
-$122.85 M |
-$65.39 M |
-$102.31 M |
-$52.21 M |
-$17.33 M |
| EBITDA Ratio |
0.03
|
-0.15
|
-0.73
|
-1.59
|
-3.42
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.04
|
-0.26
|
-0.59
|
-1.7
|
-9.06
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$709.00 K
|
$694.00 K
|
-$53.27 M
|
-$10.85 M
|
$89.46 M
|
$1.03 M
|
$2.21 M
|
-$14.43 M
|
| Income Before Tax |
-$21.43 M
|
-$86.91 M
|
-$162.42 M
|
-$142.07 M
|
-$83.95 M
|
-$103.26 M
|
-$52.53 M
|
-$17.35 M
|
| Income Before Tax Ratio |
-0.04
|
-0.26
|
-0.87
|
-1.84
|
-4.39
|
0
|
0
|
0
|
| Income Tax Expense |
$1.94 M
|
$1.03 M
|
$991.00 K
|
-$6.41 M
|
$37.00 K
|
$6.00 K
|
$21.00 K
|
$0.00
|
| Net Income |
-$23.36 M
|
-$87.94 M
|
-$163.42 M
|
-$135.67 M
|
-$83.99 M
|
-$103.27 M
|
-$52.55 M
|
-$17.35 M
|
| Net Income Ratio |
-0.04
|
-0.26
|
-0.88
|
-1.76
|
-4.39
|
0
|
0
|
0
|
| EPS |
-0.47 |
-1.85 |
-4 |
-4.01 |
-2.77 |
-4.09 |
-2.29 |
-0.75 |
| EPS Diluted |
-0.47 |
-1.85 |
-4 |
-4.02 |
-2.77 |
-4.09 |
-2.29 |
-0.75 |
| Weighted Average Shares Out |
$50.20 M
|
$47.52 M
|
$40.89 M
|
$33.84 M
|
$30.32 M
|
$25.25 M
|
$22.99 M
|
$22.99 M
|
| Weighted Average Shares Out Diluted |
$50.20 M
|
$47.52 M
|
$40.89 M
|
$33.98 M
|
$30.32 M
|
$25.25 M
|
$22.99 M
|
$22.99 M
|
| Link |
|
|
|
|
|
|
|
|
